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Serum S100A12 and S100B proteins are independent predictors of the presence and
severity of obstructive sleep apnea
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Background/aim: Obstructive sleep apnea (OSA) is associated with serious cardiometabolic risks. Early diagnosis and treatment
compliance are important. For this purpose, research is being carried out on biomarkers associated with the pathogenesis of the
disease. We aimed to investigate whether serum S100A12 and S100B proteins could be used as biochemical markers in OSA patients to
determine disease presence and severity.
Materials and methods: A total of 60 (16 women, 44 men) patients with OSA and 50 (20 women, 30 men) controls were enrolled in
this cross-sectional study. Each subject included in the study underwent full-night polysomnography (PSG). The presence and severity
of OSA was assessed with the apnea–hypopnea index (AHI). In the OSA group, 17 cases were mild, 18 were moderate, and 25 were
severe. The serum levels of S100A12 and S100B were measured using the enzyme-linked immunosorbent assay (ELISA) technique.
These protein levels were compared using Student’s t-test in the patient and control groups. Spearman’s rho correlation coefficients and
corresponding P-values were calculated to determine the correlations between these protein levels and polysomnographic parameters.
For evaluating the association between OSA and biomarkers, as well as possible confounding factors with S100A12 and S100B, we
employed multiple linear regression analyses for the patients with OSA.
Results: Serum levels of S100A12 and S100B were higher in patients than those in controls (P = 0.01 and P = 0.005, respectively), and
a significant correlation was determined between S100A12 and S100B values and AHI (P = 0.0001; P = 0.0001), sleep time with SpO2
< 90% (P = 0.032; P = 0.01), minimum SpO2 during sleep (P = 0.019; P = 0.007), and oxygen desaturation index (ODI) (P = 0.001; P
= 0.0001). In the linear regression analysis, AHI was independently related with both S100A12 (P < 0.0001) and S100B (P = 0.011).
Receiving operating curves (ROC) identified patients with OSA: AUC for S100A12 = 0.643; AUC for S100B = 0.655 (P < 0.05).
Conclusion: Serum levels of S100B and S100A proteins have high diagnostic performance in OSA and are independent predictors of
OSA presence and severity.
Key words: Obstructive sleep apnea, S100A12 protein, S100B protein

1. Introduction
Obstructive sleep apnea (OSA) is characterized by
intermittent hypoxemia and sleep disruption due to
recurrent obstruction of the upper respiratory tract during
sleep [1,2]. Due to this chronic intermittent hypoxemia
and sleep disruption, OSA can trigger the development
of systemic inflammation [3], oxidative stress [4],
endothelial dysfunction [5], and metabolic syndrome [6].
Cardiovascular and cerebrovascular complications have
been associated with oxidative stress and inflammatory
reactions in OSA [7]. Moderate to severe sleep apnea was
independently associated with a significantly increased

risk of all-cause mortality in a study of a communitybased sample [8]. Hence, early diagnosis and treatment
compliance are important to prevent morbidity and
mortality due to OSA. Polysomnography (PSG) enables
the accurate diagnosis of OSA but is time-consuming.
Therefore, OSA mostly remains undiagnosed [9].
Continuous positive airway pressure (CPAP) is highly
efficacious, but a significant proportion of patients have
poor adherence to therapy [10]. OSA-related biomarkers
have the potential to provide information about the
diagnosis, severity, prognosis, and treatment adherence
of the disease [9]. To date, many inflammatory markers
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shown to be associated with OSA have been reported,
such as C-reactive protein (CRP), tumor necrosis factoralpha (TNFa), interleukin-6 (IL-6), IL-8, intercellular
cell adhesion molecules (ICAMs), vascular cell adhesion
molecules (VCAMs), and selectins [11]. However, their
specificity and sensitivity have not been researched,
nor have they been shown to be decisively reduced with
treatment. In addition, the inflammatory markers have
been shown to be influenced by many factors other than
OSA. Therefore, there is still no ideal substance that can be
used as a biomarker [9].
In clinical studies, it has been reported that the serum
concentrations of calgranulins in the S100A12 and S100B
proteins may be used as biological markers of cell stress
[12]. There have been studies showing that in patients with
OSA, an increase in these proteins may be associated with
the disease [13–15]. S100A12 has been shown to be present
on circulating leukocytes and is considered a susceptible
marker for the local inflammatory process associated with
oxidative stress [16]. S100A12 is a ligand for the receptor
for advanced glycation end products (RAGE). RAGE
expression has previously been shown to be affected by
hypoxia via hypoxia inducible factor-1 [16]. RAGE plays a
major role in inflammatory events, such as atherosclerosis
[12]. Extracellular S100B interacts with RAGE and leads
to nuclear factor-κB (NF-κB) activation. By binding
and activating S100B, RAGE has been shown to induce
inflammatory gene expression and facilitate oxidative
inflammation [17]. In recent years, the S100B protein has
been largely emphasized as the biochemical marker of
cerebral diseases [18], and there are experimental animal
studies demonstrate that S100B proteins induce similar
intermittent hypoxia-associated neuronal degeneration as
that seen in OSA [19].
This study aims to investigate whether serum S100A12
and S100B levels are associated with the presence and
severity of OSA disease and whether these proteins may be
biomarkers that reflect the presence and severity of OSA.
2. Materials and methods
This cross-sectional study was conducted between January
2015 and March 2016.
2.1. Study group
Full-night PSG was performed for those who had been
admitted to the sleep clinic (age range: 18-70 years).
Patients were asked to provide a detailed medical history
and underwent a basic medical examination for the
following: weight, height, and heart and respiratory system
inspection. The body mass index (BMI) was calculated by
dividing the weight of the patient by the height squared
(kg/m²). Comorbid disorders were identified by lung
function tests, chest radiography, electrocardiography, and
blood tests (liver and renal function tests, fasting blood
sugar, blood fats, hemoglobin, hematocrit, sedimentation).

OSA was diagnosed when the patient’s apnea–hypopnea
index (AHI) score was ≥ 15 events/h or ≥ 5 events/h
with daytime sleepiness and/or the patient had habitual
snoring or apnea complaints from a partner (n = 60).
Subjects with AHI < 5 were included in the control
group (n = 50). In total, 706 (566 OSA, 140 non-OSA)
patients were examined with PSG in the sleep laboratory
for 1 year, and 110 were included in the study. Patients
with diagnoses of central sleep apnea or Cheyne-Stokes
respiration (n = 7), the clinical manifestation of severe
chronic obstructive pulmonary disease (COPD), or
asthma (postbronchodilator FEV1 < 70% predicted)
(n = 160) were excluded. Exclusions included a history
of cerebrovascular or cardiovascular disease (n = 263),
chronic renal insufficiency (19), diabetes (256), acute
infection (5), rheumatologic disorder (15), or cirrhosis
(3); 100 patients had both diabetes and vascular disease, 37
had both pulmonary disease and coronary artery disease,
and 7 had all 3. Twelve patients did not agree to participate
in the study. The protocol was approved by the Ethics
Committee of Necmettin Erbakan University, Meram
Medical School (number: 2015/183). Written informed
consent was obtained from all subjects.
2.2. Polysomnography (PSG)
Full-night PSG was conducted for all subjects using a digital
PSG system (Somnoscreen Plus, Somnomedics GmbH,
Randersacker, Germany) in our sleep laboratory. PSG
results were analyzed by a doctor according to the updated
criteria of the American Academy of Sleep Medicine [20].
A reduction in peak signal excursions by ≥ 90% of preevent
baseline for at least 10 s was considered apnea, a reduction
in nasal pressure signal excursions by ≥ 30% of baseline
together with arousal or ≥ 3% desaturation from preevent
baseline for at least 10 s was considered hypopnea, and
partial and/or complete airflow cessation with ongoing
thoracoabdominal effort was considered an obstructive
event. The number of apneas and/or hypopneas per hour
of sleep during the study was defined as AHI. OSA severity
was classified as mild (5 < AHI ≤ 15), moderate (15 < AHI
< 30), or severe (AHI ≥ 30) [20].
During PSG, the following variables were recorded:
sleep efficiency (SE), calculated as the total sleep time
multiplied by time spent in bed; minimum oxygen
saturation (minimum SpO2), the lowest oxygen saturation
recorded during sleep; mean oxygen saturation (mean
SpO2), the average oxygen saturation recorded during
sleep; sleep time SpO2 < 90%, the amount of sleep time
spent at < 90% of the oxygen saturation level; oxygen
desaturation index (ODI), the number of ≥ 3% arterial
oxygen desaturations per hour of sleep; rapid eye
movement (REM) sleep ratio %, the ratio of REM sleep
duration to total sleep duration; and NREM sleep ratio
%, the ratio of nonREM3 sleep duration to total sleep
duration.
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2.3. S100A12 and S100B serum level assays
Blood samples from patients and controls were collected
at the end of the PSG recording, between 07:00 and 08:00.
Samples were centrifuged at 5000 g at 4 °C for 5 min within
1 h of collection. Serum was stored at –80 °C before further
use, and all samples were processed in the same manner.
S100A12 and S100B serum levels were measured by enzyme-linked immunosorbent assays (ELISAs), using commercially available kits for S100A12 and S100B proteins.
2.4. Statistical analysis
SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) was used
for the analysis. The Kolmogorov-Smirnov test was performed to determine if the continuous numerical variables were normally distributed. Group comparisons for
variables that fit a normal distribution were performed by
parametric methods. Student’s t-test for two independent
group comparisons (i.e., the analysis of variance [ANOVA]
for multiple group comparisons) was used. The MannWhitney U-test and the Kruskal-Wallis variance analysis
were used for nonnormally distributed variables. Results
are presented as median and interquartile range (IQR)
values. In order to determine the correlations between
categorical variables, the exact (Monte Carlo) corrected
chi-square analysis method was preferred. Spearman’s rho
correlation coefficients and corresponding P-values were
calculated to determine the correlations between numerical variables. Ordinal logistic regression was executed to
identify which of the predictors were significantly contributing to OSA severity. For evaluating the association
between OSA and biomarkers, as well as possible confounding factors with S100A12 and S100B, we employed
multiple linear regression analyses for the patients with
OSA. In this analysis, we used serum levels of S100A12
and S100B as the dependent variables and evaluated the
order of inclusion in the model of the following independent variables: age, sex, BMI, mean SpO2, ODI, sleep time
with SpO2 < 90%, and AHI. A value of P < 0.05 was consid-

ered statistically significant. Sensitivity and specificity of
S100A12 and S100B were based on the standard formulas
of receiving operating curves (ROC).
3. Results
The study group consisted of 110 participants including
60 OSA patients (16 women [26.7%] and 44 men [73.3%])
and 50 controls (20 women [40%] and 30 men [60%]). In
the OSA group, 17 (28%) were mild, 18 (30%) were moderate, and 25 (42%) were severe.
There was no statistically significant difference between
the groups regarding age or sex (P = 0.252, P = 0.152). The
BMIs of patients with OSA were significantly higher than
those of the control group (P = 0.002) (Table 1). There was
no statistically significant difference between the groups
in terms of SE (P = 0.256), but the other PSG data were
statistically significantly different between the 2 groups.
The values for minimum oxygen saturation, mean SpO2,
sleep time with SpO2 < 90%, ODI, REM sleep duration,
and NREM sleep duration were 82 (7.75) vs. 89 (3.50), 93
(4) vs. 94 (2), 5.50 (36.50) vs. 0 (2), 22 (95) vs. 5(1), 10 (15)
vs. 8 (8.50), 3 (10) vs. 5 (11) in OSA and in the control
groups, respectively (all P < 0.05).
3.1. Serum S100A12 and S100B levels
S100A12 and S100B levels of patients with OSA were
significantly higher than those in the control group (P =
0.001 and P = 0.005, respectively) (Table 1). Among the
3 subgroups of OSA patients, serum S100A12 levels rose
with the severity of the disease (Figures 1–2).
The control group’s S100A12 levels were mean 314
(IQR:201) ng/mL in males and mean IQR:321.50 (208.75)
ng/mL in females. In the OSA group, S100A12 levels were
mean 426 (IQR:1053.75) ng/mL in men and mean 314.50
(IQR:214.50) ng/mL in women. The control group’s S100B
levels were mean 253 (IQR:159) pg/mL in males and mean
232.50 (IQR:147.75) pg/mL in females. The S100B levels in
the OSA group were mean 384 (IQR:877) pg/mL in males
and mean 317.50 (IQR:236) pg/mL in females. There was

Table 1. Clinical and biochemical characteristics of controls and OSA patients.
OSA group Median (IQR)

Control group Median (IQR)

Age (year)

49 (18.50)

46 (23)

P
0.252

BMI (kg/m2)

30 (7)

28 (6.50)

0.002*

AHI (event/h)

24 (51.25)

5 (2.50)

0.000*

S.E. (%)

76 (19.75)

80 (14.50)

0.256

S100A12 ng/mL

421 (759.75)

314 (197)

0.001*

S100B pg/mL

358 (888)

241 (143)

0.005*

*P < 0.05. IQR: interquartile range, OSA: obstructive sleep apnea, BMI: body mass index,
AHI: number of apneic hypopneas per hour, SE: sleep efficiency.
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Figure 1. Serum S100A12 levels in control group and mild, moderate, and severe OSA patients.

Figure 2. Serum S100B levels in control group and mild, moderate, and severe OSA patients.
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no statistically significant difference between the males
and females in either group concerning S100A12 and
S100B levels (P = 0.784 and P = 0.082, respectively and P =
0.903 and P = 0.12, respectively).
3.2. Correlations
In the OSA group, a significant, moderate positive
correlation was determined between the AHI scores and
ODI with S100A12 (P = 0.0001; r = 0.525 and P = 0.001;
r = 0.531) and S100B values (P = 0.0001; r = 0.531 and
P = 0.0001; r = 0.520). In the study group, statistically
significant weak positive correlation was observed
between the time SpO2 < 90% values and S100A12 levels
(P = 0.032; r = 0.277) and S100B levels (P = 0.01; r = 0.33).
Additionally, in the study group, a statistically significant
weak positive correlation was observed between the
minimum SpO2 values and S100A12 levels (P = 0.019; r
= –0.303) and S100B levels (P = 0.007; r = –0.345). There
was no correlation between the REM and NREM3 sleep
time ratios and the S100A12 or S100B protein serum levels
(Table 2). Moreover, no significant correlation was detected
between age and S100A12 (P = 0.760; r = –0.040) or S100B
(P = 0.626; r = 0.064) proteins in the subjects included in the

study. Ordinal logistic regression was executed to identify
which of the predictors were significantly contributing to
OSA severity. Age (P = 0.19, not significant), male sex (P =
0.007), BMI (P = 0.001), S100A12 (P = 0.0006), and S100B
(P = 0.0002) were found to have significant effects on OSA
severity. Odds ratios were 1.02 (95% confidence interval
[CI]: 0.99–1.05), 3.55 (95% CI: 1.41–8.93), 1.14 (95% CI:
1.05–1.23), 1.001 (95% CI: 1.0–1.002), and 1.001 (95% CI:
1.001–1.002), respectively.
For evaluating the association between OSA and
biomarkers, as well as possible confounding factors
with S100A12 and S100B, we employed multiple
linear regression analyses for the patients with OSA.
According to this analysis, the main factor affecting
S100A12 was found to be AHI (P = 0.002). Age, male
sex, BMI, min. SpO2, ODI, and sleep time under
90% had no significant effect on S100A12 levels
Likewise, only AHI was a main factor affecting the level of
S100B (P = 0.003) (Table 3).
3.3. Positive and negative predictive values
In this study, when 315 ng/mL was used as a threshold for
S100A12, the results obtained had a sensitivity of 75.0%,

Table 2. The correlations of S100A12 and S100B levels with polysomnographic
parameters in both groups.

AHI events/h
Minimum SpO2 (%)
Mean SpO2 (%)
Time SpO2 <90% (%)
ODI (desaturation/h)
REM sleep ratio (%)
NREM3 sleep ratio (%)
BMI kg/m2
S100A12 ng/mL

OSA group

Control group

S100A12

S100B

S100A12

S100B

r

0.525

0.531

0.034

–0.098

p

0.0001*

0.0001* 0.818

0.503

r

–0.303

–0.345

0.042

0.080

p
r
p

0.019*
–0.043
0.745

0.007*
–0.125
0.340

0.775
0.047
0.751

0.584
0.002
0.991

r

0.277

0.330

–0.203

–0.200

p
r
p
r
p
r
p
r
p
r
p

0.032*
0.531
0.0001*
–0.083
0.530
–0.082
0.531
0.33
803
1

0.010*
0.520
0.0001*
–0.187
0.152
–0.160
0.221
–0.52
697
938
0.00*

0.162
0.040
0.770
0.187
0.199
–0.207
0.153
0.223
0.87
1

0.168
0.085
0.550
0.115
0.433
–0.181
0.214
0.208
0.110
0.877
0.00*

BMI: body mass index, AHI: number of apneic hypopneas per hour, ODI:
oxygen desaturation index. *P < 0.05.
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specificity of 51%, positive predictive value of 65.2%,
negative predictive value of 62.5%, and accuracy of 64.2%.
When the threshold used for S100B was 254 pg/mL, the
results had 75.0% sensitivity, 55.1% specificity, 67.2% positive predictive value, 64.3% negative predictive value, and
66.05% accuracy. ROC curve identified patients with OSA

significantly; the area under the curve (AUC) for S100A12
= 0.643, P = 0.01; AUC for S100B = 0.655, P = 0.005] (Figure 3).
3.4. Tables and figures
Table 1. Clinical and biochemical characteristics of controls and OSA patients.

Table 3. Multiple linear regression analyses predicting relation level of S100A12 and S100B with possible
confounding factors in patients with OSA.
Parameter estimates for S100A12

Parameter estimates for S100B

Parameter

DF Estimate Std. Er t

Pr > |t| Estimate Std. Er

Intercept

1

0.39

1269.70

1487.4 –0.85

–359.79

t

Pr > |t|

1360.97 –0.26 0.79

Age(year)

1

2.78

5.05

0.55

0.58

1.67

4.62

0.36

0.71

Sex (male)

1

130.89

144.93 0.90

0.36

145.18

132.60

1.09

0.27

BMI (kg/m2)

1

8.39

12.86

0.65

0.51

–0.68

11.77

–0.06 0.95

Min SpO2 (%)

1

9.97

12.94

0.77

0.44

5.75

11.84

0.49

0.62

ODI (desaturation)/h

1

5.02

7.00

0.72

0.47

1.59

6.40

0.25

0.80

Sleep time <90%

1

1.07

3.42

0.31

0.75

2.25

3.13

0.72

0.47

AHI (event/h)

1

10.41

3.19

3.25

0.00*

9.03

2.92

3.09

0.00*

BMI: body mass index; AHI: number of apneic hypopneas per hour; ODI: oxygen desaturation index.
Std. Er: Standard error. DF: degree of freedom. * P > |t| <0.05.

Figure 3. ROC curves for S100A12 and S100B.
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Table 2. Correlation of S100A12 and S100B levels with
PSG parameters in both groups.
Table 3. Multiple linear regression analyses predicting
relation level of S100A12 and S100B with possible
confounding factors in the patients with OSA.
Figure 1. Serum S100A12 levels in control group and mild,
moderate, severe OSA patients.
Figure 2. Serum S100B levels in control group and mild,
moderate, severe OSA patients.
Figure 3. ROC curves for S100A12 and S100B.
4. Discussion
In this study, we detected that S100A12 and S100B levels
were higher in the OSA group than in the control and that
there was a positive correlation between OSA severity and
these protein levels. According to our study, the minimum
SpO2, sleep time SpO2 < 90%, and ODI values in the OSA
group were correlated with the S100A12 and S100B values.
These calcium-binding proteins from the S100 family have
been shown to be present on circulating leukocytes and are
considered to be susceptible markers for the inflammatory
process associated with oxidative stress [16,21]. However,
the main factor affecting the S100A12 level was AHI in our
study. In addition, S100A12 levels correlated to the level of
severity of disease in OSA patients. In a study conducted
in China, it was found that S100A12 levels increased
with increasing OSA severity. However, only men were
included in the study, and the association between any
PSG data other than AHI and the S100A12 protein level
was not investigated [15]. In the OSA group, the origin
of the S100A12 protein was reported to be upper airway
inflammation.
Obesity is an important risk factor for OSA. OSA and
obesity share common mechanisms such as: activation of
inflammation, oxidative stress, and increased sympathetic
activity [22]. In the study of Shi, the patient and control
group BMIs were calculated as 26.48 ± 4.15 kg/m2 and
26.47 ± 2.38 kg/m2, respectively (P = 0.975); although
there was no difference between groups in terms of BMI,
S100A12 was found to be higher in the OSA group [15]. In
our study, BMI averages in both OSA and control groups
were overweight, but were significantly higher in the
OSA group than in the control group. However, BMI was
not found to be a significant predictor in the regression
analysis established to estimate S100A12 or S100B levels.
The S100B Ca2+-binding protein has both intracellular
and extracellular functions. RAGE has been recently shown
to lead to NF-κB activation and facilitate oxidative events
in monocytes, macrophages, microglia, and neutrophils by
binding and activating S100B [17]. In our study, increasing
levels of S100B showed a weak negative correlation with
levels of oxygen saturation at night. However, in our
study the main factor affecting the S100B level was AHI.
Repeated sleep apneic episodes may lead to behavioral and

752

morphological brain alterations in patients with OSA. A
decrease in the gray matter volume in the right middle
temporal gyrus in patients with OSA has been observed
[23], and the same area was shown to be susceptible to
hypoxic damage in an animal model of OSA [24]. An
increase in S100B may reflect glial damage or reactive
astrogliosis, an astrocytic reaction to neural injury, which
may have neuroprotective properties [25]. S100B protein
has been largely emphasized as the biochemical marker
of cerebral diseases [18]. Our results are similar to the
results of Riad et al. [26], who found that S100B serum
levels were higher in patients than in controls, and that
the level of S100B was correlated with AHI, lowest oxygen
saturation, and ODI. In OSA, cerebral damage may occur
following hypoxia. An animal study demonstrated that
activation of the RAGE/NF-κB pathway induces neuronal
degeneration, whereas activation of the S100B/RAGE/
NF-κB pathway leads to reactive gliosis in the sleep apnea
model of intermittent hypoxia exposure [19] Braga et al.
[13] showed that there was an increase in S100B protein
levels in OSA patients compared to a control group, but
S100B did not correlate significantly with AHI score or
minimum SpO2. In another study, Duru et al. [14] found
that S100B levels were significantly higher in patients with
OSA than in controls, but could not detect any significant
correlations with AHI, minimum SpO2, mean SpO2, or
sleep time SpO2 < 90% parameters.
Recently, Shih and Malhotra [27] described the
properties required for an ideal biomarker for sleep apnea,
suggesting that optimal biomarkers would be a tool for
assessing diagnostic measures, burden, and severity of
disease, as well as a method of measuring response to
treatment [1]. If the biomarker is in a causal path known
to be important in disease complications, changes in
biomarker levels in response to treatment can be a reliable
predictor of serious medical complications and allow the
ideal biomarker to be used as a representative outcome
measure in clinical trials. Two recent studies reported
a significant decrease in serum S100B protein level with
CPAP therapy in OSA patients [28,29].
In our study, when the thresholds used for S100A12
and S100B were 315 ng/mL and 254 pg/mL, respectively,
the specificity and sensitivity were moderate, but when
the AUC was examined, the ROC curve significantly
identified patients with OSA. Similarly, in the study of Shi
et al., S100A12 levels were reported to exhibit moderate
sensitivity (83.33%) and specificity (66.22%) in showing
the presence of OSA [15].
The confounding factors that are difficult to exclude in
patients with OSA, such as age, BMI, and body fat mass,
have been shown to play a role in many inflammatory
markers previously shown to be associated with OSA.
A recent metaanalysis has shown that increases in
inflammatory marker levels (including CRP, TNFa, IL-
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6, IL-8, ICAMs, VCAMs, and selectins) in OSA patients
positively influenced the severity of the disease. However,
a metaregression analysis has reported that age and BMI
have moderate but significant effects on all inflammatory
markers in OSA patients [11].
One limitation of our study was that the cognitive
functions and daytime sleepiness of the patients were
not investigated. An investigation of these conditions
may give more information about the factors affecting
S100B protein levels. Moreover, changes in the protein
levels due to treatment were not evaluated. We included
a selection of OSA population of both genders without
serious comorbidities, but this population does not reflect
the general population since patients with OSA have
occasional comorbidities.

Our study suggests that serum levels of S100B and
S100A12 proteins have diagnostic performance in OSA and
are independent predictors of OSA presence and severity.
In our study, it was found that age, gender, or BMI did not
have an effect on S100A12 and S100B protein levels. This
suggests that these proteins may be superior biomarkers
to those previously described. These biomarkers also have
the potential to improve assessments of prognoses and
responses to treatment.
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